Quantib, a specialist in artificial intelligence solutions for precision diagnosis, is launching the newest update of the Quantib Prostate solution, Quantib Prostate 1.3.
This software for prostate MRI reading support has a class IIb CE marking under the new MDR laws and FDA clearance for clinical use in the United States.
Dan Sperling, MD, said: “Quantib has been an incredibly responsive and innovative company. Their constructive use of feedback and suggestions is part of contributing to a team effort toward product development and solutions. I am pleased with the frequency with which they bring new features and product enhancements each quarter.”
Quantib Prostate, using deep learning algorithms, aims to advance the MRI prostate reporting workflow and is accessible directly from the radiologist’s reading station. Moreover, the solution comes with a suite of tools to improve reporting quality and speed: including AI-based volumetry and PSA density calculation, precise registration and movement correction, one-click segmentation of lesion candidates, classification, PI-RADS scoring support and standardised reporting to facilitate easy and comprehensive communication of results. The upgrade includes:
- Kinetic curve representation per ROI and of the full prostate gland
- Visual PI-RADS v.2.1 scoring support including ROI marking
- Compatibility with multiple ultrasound systems to import 3D gland and lesion segmentations
Quirine van Voorst, Quantib’s COO said: “The most important thing for us is listening to our clients and incorporating their feedback to improve our products taking their wishes into account. We have worked very hard to improve compatibility and further optimise the AI-powered reports according to our customers’ needs and we look forward to rolling out this update in the coming weeks.”
